Are you Dr. Waxman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 10 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3959 Broadway
Columbia Uni Departmt Prds
New York, NY 10032Phone+1 212-304-7250Fax+1 212-544-1974
Summary
- Dr. Ian Waxman, MD is a pediatrician in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York University School of MedicineClass of 2002, MD
Certifications & Licensure
NY State Medical License 2003 - 2025
Publications & Presentations
PubMed
- 5 citationsErratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma...Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers
European Urology. 2018-04-01 - 200 citationsCheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers
European Urology. 2017-12-01 - 55 citationsEvaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.Shruti Agrawal, Paul Statkevich, Gaurav Bajaj, Yan Feng, Sally Saeger
Journal of Clinical Pharmacology. 2017-03-01
Press Mentions
Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) plus Yervoy (Ipilimumab) as First-Line Treatment for Patients With…April 5th, 2022- Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) with Chemotherapy as First-Line Treatment for Patients With…April 5th, 2022
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …October 21st, 2021
- Join now to see all
